| Literature DB >> 28341065 |
Anja Hviid Simonsen1, Sanna-Kaisa Herukka2, Niels Andreasen3, Ines Baldeiras4, Maria Bjerke5, Kaj Blennow6, Sebastiaan Engelborghs7, Giovanni B Frisoni8, Tomasz Gabryelewicz9, Samantha Galluzzi10, Ron Handels11, Milica G Kramberger12, Agnieszka Kulczyńska13, Jose Luis Molinuevo14, Barbara Mroczko15, Agneta Nordberg16, Catarina Resende Oliveira4, Markus Otto17, Juha O Rinne18, Uroš Rot12, Esen Saka19, Hilkka Soininen2, Hanne Struyfs5, Silvia Suardi20, Pieter Jelle Visser21, Bengt Winblad22, Henrik Zetterberg23, Gunhild Waldemar24.
Abstract
This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.Entities:
Keywords: Alzheimer's disease; Biomarkers; CSF; Diagnosis; GRADE; Recommendations
Mesh：
Substances：
Year: 2016 PMID： 28341065 DOI： 10.1016/j.jalz.2016.09.008
Source DB: PubMed Journal: Alzheimers Dement ISSN： 1552-5260 Impact factor: 21.566